AG
AIMT

Artal Group’s Aimmune Therapeutics AIMT Stock Holding History

Artal Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,000
Closed -$2.06M – 125
2017
Q2 		$2.06M Sell
100,000
-81,600
-45% -$1.56M 0.04% 96
2017
Q1 		$3.95M Buy
181,600
+100,000
+123% +$2.05M 0.09% 68
2016
Q4 		$1.67M Buy
+81,600
New +$1.67M 0.04% 81

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Artal Group's AIMT Position: Q3 2017 in Review

Artal Group sold out of Aimmune Therapeutics (AIMT) in Q3 2017, closing a stake of 100,000 shares — an estimated $2.06M sold.

Artal Group first reported a position in AIMT in Q4 2016 and held it in 3 quarters. The position peaked at $3.95M in Q1 2017. 100 funds tracked by Wall St. Rank hold AIMT as of Q3 2017.

  • Artal Group reported no remaining Aimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Artal Group sold 100,000 Aimmune Therapeutics shares in Q3 2017, an estimated $2.06M.
  • Artal Group first reported a position in Aimmune Therapeutics in Q4 2016 and held it in 3 quarters.
  • Artal Group's Aimmune Therapeutics position peaked at $3.95M in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2017.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.